Small molecule · Modulator of serotonin transporter (SLC6A4) · developed by Takeda Pharms Usa
Vortioxetine is an oral small molecule that inhibits serotonin reuptake and also acts as a 5-HT3 receptor antagonist and 5-HT1A receptor agonist in the central nervous system. It is used in the treatment of major depressive disorder.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 23, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07204314 | Phase 3 | Major Depressive Disorder | Recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Major Depressive Disorder
Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →